What is BSEM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BSEM?

P/E (TTM) is n/a and 52-week range is $1.11 to $8.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BSEM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BSEM?

The company profile lists net income (TTM) near -$22M, EPS (TTM) near -$1.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Biostem Technologies Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Pompano Beach, Florida, US, 18.7M shares outstanding, ISIN US0906842002 when available from company profile and filing metadata.

Biostem Technologies Inc

$BSEM

Health Care · Pharmaceuticals

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Biostem Technologies Inc

$BSEM

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The firm's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. The company also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.

Website

www.biostemtechnologies.com/

IPO

2001-07-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

OTC MARKETS

ISIN

US0906842002

Headquarters

Pompano Beach, Florida, US

Shares outstanding

18.7M

NAICS sector

Manufacturing

Browse other companiesFree AI scores and summaries for more stocks

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The firm's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. The company also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.

Website

www.biostemtechnologies.com/

IPO

2001-07-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)